Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06623110 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
A Phase 2 study of High-Risk Oral Precancerous Disease, sponsored by Glenn J. Hanna.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT06623110: Recruiting Phase 2 study of High-Risk Oral Precancerous Disease, sponsored by Glenn J. Hanna.
NCT06623110 is a Phase 2 study of High-Risk Oral Precancerous Disease that is actively recruiting participants, run by Glenn J. Hanna. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06623110, a Phase 2 study of High-Risk Oral Precancerous Disease, is actively recruiting participants, sponsored by Glenn J. Hanna.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to understand the safety, tolerability, and potential efficacy of an injected immune therapy called RP2 to treat oral precancer conditions and prevent progression to an oral cancer. The name of the study drug involved in this study is: -RP2 (a genetically modified live Herpes Simplex V-1 strain)
Primary Outcome
The best overall response is the best response recorded from the start of the treatment until disease progression (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Responses do not require confirmation. Complete response (CR) is complete disappearance of all target lesions. Partial response (PR) is at least 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Conditions Studied
Interventions
- BIOLOGICAL RP2 Injection
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2029-01-01 |
| Phase | Phase 2 |
What NCT06623110 shows while recruiting
NCT06623110 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with High-Risk Oral Precancerous Disease appearing as the primary indexed condition, and to 1 intervention - of which RP2 Injection is the first listed.
NCT06623110 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06623110 about?
NCT06623110 is a clinical study titled "Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease". The goal of this study is to understand the safety, tolerability, and potential efficacy of an injected immune therapy called RP2 to treat oral precancer conditions and prevent progression to an oral cancer. The name of the study drug involved in this study is: -RP2 (a genetically modified live He...
What is the current status of trial NCT06623110?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-01-01. Estimated completion is 2029-01-01.
What conditions does trial NCT06623110 study?
This clinical trial studies the following conditions: High-Risk Oral Precancerous Disease.
What interventions are being tested in trial NCT06623110?
The interventions under investigation include: RP2 Injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT06623110?
This trial is sponsored by Glenn J. Hanna, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06623110 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06623110's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI